Glucose-Methotrexate Conjugate for Selective Autoimmune Cell Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases like rheumatoid arthritis and psoriasis using methotrexate suffer from high toxicity and limited efficacy due to systemic side effects, leading to discontinuation of therapy in approximately 30% of patients.
Innovation Solution
A glucose-methotrexate conjugate is developed, where glucose is linked to methotrexate via a cleavable linker to enhance bioavailability, selectivity, and reduce toxicity, utilizing the increased glucose demand of inflammatory cells and overexpression of GLUT transporters.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If methotrexate is used to treat autoimmune diseases, then therapeutic efficacy is achieved, but toxicity increases leading to discontinuation of therapy
Solution Approach 1:
The patent introduces glucose as an intermediary carrier molecule that facilitates the delivery of methotrexate to inflammatory cells. The glucose-methotrexate conjugate acts as a mediator that exploits the glucose transport mechanisms of inflammatory cells to achieve selective drug delivery, thereby maintaining therapeutic efficacy while reducing non-specific toxicity to healthy tissues.
Solution Approach 2:
The patent applies local quality by creating a conjugate that targets specific tissues with high glucose demand (inflammatory cells) rather than distributing methotrexate systemically. The glucose moiety provides local specificity through recognition by GLUT transporters in inflamed tissues, concentrating the therapeutic effect where needed and minimizing harmful effects elsewhere.
2Reliability
If methotrexate dose is increased to improve efficacy, then therapeutic response increases, but toxicity increases leading to discontinuation
Solution Approach 1:
The patent changes the pharmacokinetic parameters of methotrexate by conjugating it to glucose. This modification alters the drug's absorption, distribution, metabolism, and excretion characteristics. The conjugate exhibits prolonged circulation half-life and enhanced cellular uptake through glucose transporters, allowing for lower effective doses that avoid toxicity while maintaining therapeutic response.
3Quantity of substance
If methotrexate bioavailability is improved, then drug concentration in target tissues increases, but systemic toxicity increases
Solution Approach 1:
Glucose serves as a mediator that enables selective delivery of methotrexate to target tissues through the glucose transport system. The conjugate exploits the high glucose demand of inflammatory cells to achieve concentrated drug delivery in target tissues while avoiding non-specific absorption that would cause systemic toxicity.
Solution Approach 2:
The glucose-methotrexate conjugate provides local quality by directing drug accumulation specifically to tissues with high glucose transporter expression (inflammatory cells). This spatial specificity increases drug concentration in target tissues while minimizing systemic exposure and associated toxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugate demonstrates strong inhibitory effects on affected cells, reduced cytotoxicity in healthy cells, and prolonged activity in the bloodstream, offering improved therapeutic efficacy and safety.
Implementation Method 1
The hypothesis is based on the observation of specific biochemical and pathophysiological characteristics of cells in autoimmune diseases, such as increased glucose demand of hyperproliferating cells or overexpression of GLUT family transporters
Implementation Method 2
a compound was designed in which glucose is linked to the therapeutic compound via a linker
Data Source
Figure 1~2
Figure 3~4
AI summary
The invention relates to a glucose-methotrexate conjugate for use in the prevention or treatment of autoimmune diseases, in particular rheumatoid arthritis or psoriasis.